Tryptamine Therapeutics (AU:TYP) has released an update.
Renowned psychopharmacologist Dr. Robin Carhart-Harris has recommitted to Tryptamine Therapeutics as Chair of the Scientific Advisory Board for another three years, continuing his influential work in the field of psychedelic research. Tryptamine Therapeutics, a clinical-stage biotech company, is making strides in the development of a novel IV-infused psilocin formulation, aiming to transform treatments for disorders such as fibromyalgia, binge eating, and certain types of depression. Dr. Carhart-Harris’s leadership is expected to further advance the company’s clinical trials and contribute to the innovation of precision psychedelic therapies.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.
